vs
Side-by-side financial comparison of Agilent Technologies (A) and SELECT MEDICAL HOLDINGS CORP (SEM). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $1.4B, roughly 1.3× SELECT MEDICAL HOLDINGS CORP). Agilent Technologies runs the higher net margin — 17.0% vs 1.4%, a 15.5% gap on every dollar of revenue. On growth, Agilent Technologies posted the faster year-over-year revenue change (7.0% vs 6.4%). Agilent Technologies produced more free cash flow last quarter ($175.0M vs $5.2M). Over the past eight quarters, Agilent Technologies's revenue compounded faster (6.9% CAGR vs 2.8%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Select Medical is a healthcare company based in Pennsylvania. It owns long-term acute care and inpatient rehabilitation hospitals, as well as occupational health and physical therapy clinics. Select Medical is a subsidiary of Select Medical Holdings, which is listed on the New York Stock Exchange.
A vs SEM — Head-to-Head
Income Statement — Q1 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $1.4B |
| Net Profit | $305.0M | $20.2M |
| Gross Margin | 52.6% | — |
| Operating Margin | 19.6% | 4.6% |
| Net Margin | 17.0% | 1.4% |
| Revenue YoY | 7.0% | 6.4% |
| Net Profit YoY | -4.1% | 225.7% |
| EPS (diluted) | $1.07 | $0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.7B | $1.4B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | $1.6B | $1.3B |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $20.2M | ||
| Q3 25 | $336.0M | $28.8M | ||
| Q2 25 | $215.0M | $40.6M | ||
| Q1 25 | $318.0M | $56.7M | ||
| Q4 24 | $351.0M | $-16.1M | ||
| Q3 24 | $282.0M | $55.6M | ||
| Q2 24 | $308.0M | $77.6M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 4.6% | ||
| Q3 25 | 20.7% | 5.4% | ||
| Q2 25 | 18.0% | 6.5% | ||
| Q1 25 | 22.4% | 8.3% | ||
| Q4 24 | 24.0% | 1.6% | ||
| Q3 24 | 21.1% | 4.3% | ||
| Q2 24 | 23.1% | 5.8% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 1.4% | ||
| Q3 25 | 19.3% | 2.1% | ||
| Q2 25 | 12.9% | 3.0% | ||
| Q1 25 | 18.9% | 4.2% | ||
| Q4 24 | 20.6% | -1.2% | ||
| Q3 24 | 17.9% | 4.4% | ||
| Q2 24 | 19.6% | 6.1% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $0.17 | ||
| Q3 25 | $1.18 | $0.23 | ||
| Q2 25 | $0.75 | $0.32 | ||
| Q1 25 | $1.11 | $0.44 | ||
| Q4 24 | $1.23 | $-0.12 | ||
| Q3 24 | $0.97 | $0.43 | ||
| Q2 24 | $1.05 | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $26.5M |
| Total DebtLower is stronger | $3.0B | $1.8B |
| Stockholders' EquityBook value | $6.9B | $1.7B |
| Total Assets | $12.8B | $5.9B |
| Debt / EquityLower = less leverage | 0.44× | 1.06× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $26.5M | ||
| Q3 25 | $1.5B | $60.1M | ||
| Q2 25 | $1.5B | $52.3M | ||
| Q1 25 | $1.5B | $53.2M | ||
| Q4 24 | $1.3B | $59.7M | ||
| Q3 24 | $1.8B | $191.5M | ||
| Q2 24 | $1.7B | $111.2M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $1.8B | ||
| Q3 25 | $3.4B | $1.7B | ||
| Q2 25 | $3.3B | $1.8B | ||
| Q1 25 | $3.3B | $1.8B | ||
| Q4 24 | $3.3B | $1.7B | ||
| Q3 24 | $2.1B | $3.1B | ||
| Q2 24 | $2.1B | $3.6B |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $1.7B | ||
| Q3 25 | $6.4B | $1.7B | ||
| Q2 25 | $6.1B | $1.7B | ||
| Q1 25 | $6.0B | $1.7B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $5.9B | $1.9B | ||
| Q2 24 | $6.2B | $1.4B |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $5.9B | ||
| Q3 25 | $12.2B | $5.7B | ||
| Q2 25 | $12.2B | $5.7B | ||
| Q1 25 | $11.9B | $5.7B | ||
| Q4 24 | $11.8B | $5.6B | ||
| Q3 24 | $11.0B | $8.0B | ||
| Q2 24 | $10.9B | $7.9B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 1.06× | ||
| Q3 25 | 0.53× | 1.03× | ||
| Q2 25 | 0.55× | 1.10× | ||
| Q1 25 | 0.56× | 1.03× | ||
| Q4 24 | 0.57× | 1.01× | ||
| Q3 24 | 0.36× | 1.62× | ||
| Q2 24 | 0.34× | 2.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $64.3M |
| Free Cash FlowOCF − Capex | $175.0M | $5.2M |
| FCF MarginFCF / Revenue | 9.7% | 0.4% |
| Capex IntensityCapex / Revenue | 5.2% | 4.2% |
| Cash ConversionOCF / Net Profit | 0.88× | 3.19× |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | $117.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $64.3M | ||
| Q3 25 | $362.0M | $175.3M | ||
| Q2 25 | $221.0M | $110.3M | ||
| Q1 25 | $431.0M | $-3.5M | ||
| Q4 24 | $481.0M | $125.4M | ||
| Q3 24 | $452.0M | $181.0M | ||
| Q2 24 | $333.0M | $278.2M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $5.2M | ||
| Q3 25 | $259.0M | $122.2M | ||
| Q2 25 | $107.0M | $45.6M | ||
| Q1 25 | $334.0M | $-55.8M | ||
| Q4 24 | $388.0M | $62.0M | ||
| Q3 24 | $360.0M | $130.3M | ||
| Q2 24 | $230.0M | $222.6M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 0.4% | ||
| Q3 25 | 14.9% | 9.0% | ||
| Q2 25 | 6.4% | 3.4% | ||
| Q1 25 | 19.9% | -4.1% | ||
| Q4 24 | 22.8% | 4.7% | ||
| Q3 24 | 22.8% | 10.2% | ||
| Q2 24 | 14.6% | 17.4% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 4.2% | ||
| Q3 25 | 5.9% | 3.9% | ||
| Q2 25 | 6.8% | 4.8% | ||
| Q1 25 | 5.8% | 3.9% | ||
| Q4 24 | 5.5% | 4.8% | ||
| Q3 24 | 5.8% | 4.0% | ||
| Q2 24 | 6.5% | 4.3% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 3.19× | ||
| Q3 25 | 1.08× | 6.09× | ||
| Q2 25 | 1.03× | 2.72× | ||
| Q1 25 | 1.36× | -0.06× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | 3.25× | ||
| Q2 24 | 1.08× | 3.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
SEM
| Critical Illness Recovery Hospitals | $629.7M | 45% |
| Health Care Patient Service Non Medicare | $428.6M | 31% |
| Rehabilitation Hospitals | $339.2M | 24% |
